Drug interactions of directly acting antivirals in the treatment of chronic virus hepatitis C
- Authors: Polunina T.Y.1
-
Affiliations:
- A.I. Evdokimov Moscow State Medical and Dental University
- Issue: No 3 (2017)
- Pages: 29-41
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277642
- ID: 277642
Cite item
Open Access
Access granted
Abstract
In recent years, in Russia epidemic situation on the VCH becomes apparent. Increase in morbidity of chronic hepatitis C (CHC) from 31.8 cases per 100 000 in 2005 to 39.9 per 100 000 in 2011 is observed; VHC often affects young persons, with a high Level of chronization and such possible outcomes as cirrhosis and primary liver cancer. The processes at key stages of hepatitis C virus life cycle are the main targets in the development of drugs for the treatment of chronic hepatitis C. The treatment is indicated for patients with hepatitis C with compensated and decompensated chronic liver disease, previously treated or not to receiving treatment, ready to receive therapy and with no contraindications. Through to 2011, the combination of pegylated interferon (PegIFN)-α and ribavirin for 24 or 48 weeks was officially recommended CHC treatment. After approval of three new DAAs for the treatment of CHC in Europe in 2014, wide interferon-free treatment regimens come into common use. These schemes have been used mainly for the treatment of patients with severe liver damage (stage 3-4 liver fibrosis according METAVIR scale (F3, F4)). Combination of drugs requires careful use and dose adjustment, alternation in drug intake time, and additional monitoring. Drug interactions should be especially considered when choosing a combination therapy in HCV and HIV co-infection.
Full Text
About the authors
Tatiana Ye. Polunina
A.I. Evdokimov Moscow State Medical and Dental University
Email: poluntan@mail.ru
MD, Professor of the Department of Propedeutics of Internal Medicine and Gastroenterology
References
- Carter W., Connelly S., Struble K. Reinventing HCV treatment: past and future perspectives. J. Clin. Pharmacol. 2017;57(3):287-96.
- Dhiman R.K., Satsangi S., Grover G.S., Puri P. Tackling the hepatitis C disease burden in Punjab, India. J. Clin. Exp. Hepatol. 2016;6(3):224-32.
- Gower E., Estes C., Blach S., Razavi-Shearer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014;61 (Suppl. 1):S45-57.
- Полунина Т.Е. Комплексная терапия вирусных гепатитов. Лечащий врач. 2005;9:34-41. [Polunina T.Ye. Complex therapy of viral hepatitis. Lechashchy vrach. 2005;9:34-41 (in Russ.)]
- Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2013;10:553-62.
- Ly K.N., Xing J., Klevens R.M., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012;156(4):271-8.
- Мукомолов С.Л., Левакова И.А., Сулягина Л.Г., Синайская Е.В., Болсун Д.Д., Иванова Н.В. Современная эпидемиология гепатита С в России. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012;6:21-5. [Mukomolov S.L., Levakova I.A., Sulyagina L.G., Sinaiskaya Ye.V., Bolsun D.D., Ivanova N.V. Modern epidemiology of hepatitis C in Russia. Epidemiology and infectious diseases. The actual issues. 2012;6:21-5 (in Russ.)]
- Akhtar E., Manne V., Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30-6.
- Pockros P.J. New direct-acting antivirals in the developmentfor hepatitis C virus infection. Ther. Adv. Gastroenterol. 2010;3(3):191-202.
- Ивашкин В.Т., Ющук Н.Д., Кожевникова Г.М., Маевская М.В., Маев И.В. Рекомендации по диагностике и лечению взрослых больных гепатитом С. Росс журнал гастроэнтерол. гепатол. колопроктол. 2013;23(2):41-70. [Ivashkin V.T., Yushchuk N.D., Kozhevnikova G.M., Mayevskaya M.V., Maev I.V. Guidelines for di-agnostic and treatment of adult patients with hepatitis C. Russ. J. Gastroenterol. Gepatol. Coloproc. 2013;23(2):41-70 (in Russ.)]
- Boccaccio V., Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int. 2015;35 (Suppl. 1):35-4.
- Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. J. Hepatol. 2014;61 (Suppl. 1):S69-78.
- Petta S. Hepatitis C virus and cardiovascular: A review. J. Adv. Res. 2017;8(2):161-8.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011;55(2):245-64.
- Antaki N., Craxi A., Kamal S., Moucari R., Van der Merwe S., Haffar S., Gadano A., Zein N., Lai C.L., Pawlotsky J.M., Heathcote E.J., Dusheiko G., Marcellin P. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report. Liver Int. 2010;30(3):342-55.
- Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
- Talal A.H., LaFleur J., Hoop R., Pandya P., Martin P., Jacobson I., Han J., Korner E.J. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment. Pharmacol. Ther. 2013;37(4):473-81.
- Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., DeJesus E., Pearlman B., Rabinovitz M., Gitlin N., Lim J.K., Pockros P.J., Scott J.D., Fevery B., Lambrecht T., Ouwerkerk-Mahadevan S., Callewaert K., Symonds W.T., Picchio G., Lindsay K.L., Beumont M., Jacobson I.M. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-6.
- Guidelines. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 2015;63(1):199-236.
Supplementary files
